Apocynin

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 3 countries

Funders: Fundação para a Ciência e a Tecnologia and 4 more

Animals1

Outcomes

Age-related ovarian IgG accumulation

downin mice1

1 study

Apocynin prevents age-related ovarian IgG accumulation in mice.
“In the mice, ovarian IgG staining was increased in reproductively aged animals, but not in reproductively aged animals treated with apocynin.”
Animalsreproductively aged miceovary
Ovarian ROS-dependent IgG accumulation precedes lipofuscin deposition and follicular decline: comparative insights from the bitch and mouse models of ovarian aging
Frontiers in aging30 May 2025

Cognitive function

upin mice1

1 study

Apocynin improves cognitive function in mice.
“mice treated with the NADPH oxidase inhibitor apocynin also display improved cognition and reduced microglia activation compared with controls”
Animalsin AD mouse models
Fasting-mimicking diet cycles reduce neuroinflammation to attenuate cognitive decline in Alzheimer's models
Cell reports27 Sep 2022